Clik here to view.
Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
Tuesday, April 26th 2016 at 12:30pm UTC Pfizer research program only one to assess role of PCSK9 inhibitors in reducing risk of cardiovascular events in high-risk patients without history of...
View ArticleClik here to view.
Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May
Tuesday, April 26th 2016 at 8:30pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of...
View ArticleClik here to view.
Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Wednesday, April 27th 2016 at 2:00pm UTC NEW YORK–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) will take part in the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,...
View ArticleClik here to view.
ADDING and REPLACING RxC International to Lead Gene Therapy Panel at...
Wednesday, April 27th 2016 at 3:01am UTC MORRISTOWN, N.J.–(BUSINESS WIRE)– Add after 3rd bullet point in release: Mark Scheideler, Founder, HumanFirst Therapeutics. Also adding multimedia. This Smart...
View ArticleClik here to view.
Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
Wednesday, April 27th 2016 at 8:30pm UTC NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company’s Chief Financial Officer...
View ArticleClik here to view.
Evotec to Present at Two Upcoming IR Conferences (USA)
Thursday, April 28th 2016 at 9:31am UTC HAMBURG, Germany–(BUSINESS WIRE)– Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will...
View ArticleClik here to view.
Bristol-Myers Squibb Reports First Quarter Financial Results
Thursday, April 28th 2016 at 10:59am UTC Increases First Quarter Revenues 9% to $4.4 Billion Posts First Quarter GAAP EPS of $0.71 and Non-GAAP EPS of $0.74 Achieves Significant European Regulatory...
View ArticleClik here to view.
Acorda Provides Financial and Pipeline Update for First Quarter 2016
Thursday, April 28th 2016 at 10:00am UTC AMPYRA® (dalfampridine) 1Q 2016 net revenue of $109.6 Million; 19% increase over 1Q 2015 net revenue of $92.4 Million Company exceeds 90% minimum condition to...
View ArticleClik here to view.
Foundation Medicine to Present at Upcoming Investor Conferences
Thursday, April 28th 2016 at 10:30am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company’s management team will present at the...
View ArticleClik here to view.
Pfizer Hosts Annual Meeting of Shareholders
Thursday, April 28th 2016 at 4:00pm UTC Declares 30-Cent Second-Quarter 2016 Dividend NEW YORK–(BUSINESS WIRE)– The board of directors of Pfizer Inc. today declared a 30-cent second-quarter 2016...
View ArticleClik here to view.
Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the...
Thursday, April 28th 2016 at 11:30am UTC – Globally Recognized Innovator and Distinguished Scholar in the Diagnosis and Treatment of Retinal Disorders – – Brings Extensive Organizational and...
View ArticleClik here to view.
Acorda Therapeutics to Present at Two Investor Conferences in May
Friday, April 29th 2016 at 11:00am UTC ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that the Company will present at two investor conferences during May. Deutsche...
View ArticleClik here to view.
Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate)...
Friday, April 29th 2016 at 12:00pm UTC New Pediatric Indication Provides Treatment Option for Children that Eliminates Need for Spacer and Hand-Breath Coordination During Inhalation...
View ArticleClik here to view.
Current Protocols for Screening Sperm Donors Fail to Protect Families from...
Friday, April 29th 2016 at 12:00pm UTC GenePeeks Study Compared Utility of Donor Carrier Screening Methods with Systematic Next Generation Sequence Analysis NEW YORK & CAMBRIDGE, Mass.–(BUSINESS...
View ArticleClik here to view.
22nd Century Group to Utilize Revolutionary New Filter Technology from...
Monday, May 2nd 2016 at 11:55am UTC “The most significant technological filter innovation in the last 30 years” CLARENCE, N.Y.–(BUSINESS WIRE)– Clarence, New York – 22nd Century Group, Inc. (NYSE...
View ArticleClik here to view.
22nd Century Group to Utilize Revolutionary New Filter Technology from...
Monday, May 2nd 2016 at 11:55am UTC “The most significant technological filter innovation in the last 30 years” CLARENCE, N.Y.–(BUSINESS WIRE)– Clarence, New York – 22nd Century Group, Inc. (NYSE...
View ArticleClik here to view.
Final Results of the Subsequent Offer Period of Acorda Therapeutics’ Tender...
Monday, May 2nd 2016 at 1:02pm UTC NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN...
View ArticleClik here to view.
Oligomerix Awarded a Grant for its Alzheimer’s Drug Discovery Program...
Monday, May 2nd 2016 at 2:00pm UTC NEW YORK–(BUSINESS WIRE)– Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease...
View ArticleClik here to view.
AtriCure to Present at the UBS Global Healthcare Conference
Monday, May 2nd 2016 at 8:01pm UTC MASON, Ohio–(BUSINESS WIRE)– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management,...
View ArticleClik here to view.
Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th...
Monday, May 2nd 2016 at 9:00pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing...
View Article